Scroll for more

About

 

Paul Edick
Director, Board of Directors

Mr. Paul Edick became a Director for Sucampo in July 2016. He currently serves as Founding Partner at 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was Chief Executive Officer and board member of Durata Therapeutis, a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Prior to Durata, he was Chief Executive Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, and prior to that he was Chief Executive Officer at MedPoint Healthcare, Inc. Mr. Edick has also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s Group Vice President and President for Asia and Latin America.

 He is a member of the Board of Directors of PDL BioPharma, Inc., NewLink Genetics, Inc. and Neos Therapeutics, Inc. Mr. Edick is also Chairman of the Board of Iterum Therapeutics, a private company.

Mr. Edick earned a bachelor’s degree in Psychology from Hamilton College in Clinton, NY.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.